UCB SA (UCB) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.140x

Based on the latest financial reports, UCB SA (UCB) has a cash flow conversion efficiency ratio of 0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.52 Billion ≈ $1.78 Billion USD) by net assets (€10.87 Billion ≈ $12.70 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UCB days of operational coverage to measure how many days the company can operate on defensive assets alone.

UCB SA - Cash Flow Conversion Efficiency Trend (2000–2025)

This chart illustrates how UCB SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

UCB SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of UCB SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Westinghouse Air Brake Technologies Corp
NYSE:WAB
0.018x
Toyota Tsusho Corp
NYSE:TYHOY
0.058x
Nu Holdings Ltd
NYSE:NU
0.073x
Fifth Third Bancorp
NASDAQ:FITB
-0.032x
Mercedes-Benz Group AG
F:MBG
0.029x
Franco-Nevada Corporation
TO:FNV
0.057x
Kia Corp
KO:000270
0.007x
Banco Santander Brasil SA ADR
NYSE:BSBR
0.309x

Annual Cash Flow Conversion Efficiency for UCB SA (2000–2025)

The table below shows the annual cash flow conversion efficiency of UCB SA from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see UCB SA stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €10.87 Billion
≈ $12.70 Billion
€2.16 Billion
≈ $2.53 Billion
0.199x +60.72%
2024-12-31 €10.03 Billion
≈ $11.72 Billion
€1.24 Billion
≈ $1.45 Billion
0.124x +46.05%
2023-12-31 €8.97 Billion
≈ $10.49 Billion
€761.00 Million
≈ $889.69 Million
0.085x -31.32%
2022-12-31 €9.06 Billion
≈ $10.60 Billion
€1.12 Billion
≈ $1.31 Billion
0.123x -33.34%
2021-12-31 €8.39 Billion
≈ $9.80 Billion
€1.55 Billion
≈ $1.82 Billion
0.185x +24.58%
2020-12-31 €7.27 Billion
≈ $8.50 Billion
€1.08 Billion
≈ $1.26 Billion
0.149x +18.13%
2019-12-31 €7.01 Billion
≈ $8.19 Billion
€882.00 Million
≈ $1.03 Billion
0.126x -27.72%
2018-12-31 €6.25 Billion
≈ $7.31 Billion
€1.09 Billion
≈ $1.27 Billion
0.174x +7.73%
2017-12-31 €5.74 Billion
≈ $6.71 Billion
€927.00 Million
≈ $1.08 Billion
0.162x +107.29%
2016-12-31 €5.48 Billion
≈ $6.40 Billion
€427.00 Million
≈ $499.21 Million
0.078x +75.76%
2015-12-31 €5.55 Billion
≈ $6.48 Billion
€246.00 Million
≈ $287.60 Million
0.044x -60.71%
2014-12-31 €4.89 Billion
≈ $5.72 Billion
€552.00 Million
≈ $645.35 Million
0.113x +69.44%
2013-12-31 €4.32 Billion
≈ $5.05 Billion
€288.00 Million
≈ $336.70 Million
0.067x -13.81%
2012-12-31 €4.59 Billion
≈ $5.37 Billion
€355.00 Million
≈ $415.03 Million
0.077x +27.66%
2011-12-31 €4.82 Billion
≈ $5.64 Billion
€292.00 Million
≈ $341.38 Million
0.061x -45.06%
2010-12-31 €4.59 Billion
≈ $5.37 Billion
€506.00 Million
≈ $591.57 Million
0.110x +64.99%
2009-12-31 €4.42 Billion
≈ $5.16 Billion
€295.00 Million
≈ $344.89 Million
0.067x -26.70%
2008-12-31 €4.02 Billion
≈ $4.70 Billion
€366.00 Million
≈ $427.89 Million
0.091x -20.71%
2007-12-31 €4.26 Billion
≈ $4.99 Billion
€490.00 Million
≈ $572.86 Million
0.115x +71.05%
2006-12-31 €4.78 Billion
≈ $5.59 Billion
€321.00 Million
≈ $375.28 Million
0.067x -44.19%
2005-12-31 €2.41 Billion
≈ $2.82 Billion
€290.00 Million
≈ $339.04 Million
0.120x -67.06%
2004-12-31 €1.96 Billion
≈ $2.30 Billion
€718.17 Million
≈ $839.61 Million
0.365x -3.84%
2003-12-31 €1.78 Billion
≈ $2.09 Billion
€677.97 Million
≈ $792.61 Million
0.380x -0.34%
2002-12-31 €1.57 Billion
≈ $1.83 Billion
€596.97 Million
≈ $697.92 Million
0.381x +11.99%
2001-12-31 €1.39 Billion
≈ $1.63 Billion
€473.45 Million
≈ $553.51 Million
0.341x +18.59%
2000-12-31 €1.21 Billion
≈ $1.41 Billion
€346.26 Million
≈ $404.81 Million
0.287x --

About UCB SA

BR:UCB Belgium Biotechnology
Market Cap
$56.06 Billion
€47.95 Billion EUR
Market Cap Rank
#607 Global
#3 in Belgium
Share Price
€251.90
Change (1 day)
+1.45%
52-Week Range
€155.15 - €285.40
All Time High
€285.40
About

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more